TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11115342

Group type: EXPERIMENTAL
Intervention: Active foot compression device (functioning)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo foot compression device (nonfunctioning)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Active foot compression device (functioning) - compliant subgroup
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo foot compression device (nonfunctioning) - compliant vs noncompliant
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Overall comparison of groups
Number of subjects: 115
Study: 9570681

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose-intensified chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose therapy
Number of subjects: 0
Study: 8315261

Group type: EXPERIMENTAL
Intervention: Antithrombin III supplementation (3000 units initially, followed by 1000 units every 6 hours)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 3717101

Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline sulfate, 5 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline sulfate, 7.5 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (doses adjusted to achieve serum concentrations of 10 to 20 mg/L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 20
Study: 30081329

Group type: EXPERIMENTAL
Intervention: OHRQoL measured by OHIP‐14T
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Nutritional status measured by MNA
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: HRQoL measured by WHOQOL‐BREF
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Overall model
Number of subjects: 517
Study: 28019085

Group type: EXPERIMENTAL
Intervention: Zinc-rich food
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Zinc-enriched yeast and astaxanthin oil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26694426

Group type: EXPERIMENTAL
Intervention: Viewing green scenes
Number of subjects: 46

Group type: COMPARATOR
Intervention: Viewing built scenes
Number of subjects: 46
Study: 23273853

Group type: EXPERIMENTAL
Intervention: Task-oriented mental practice (MP) approach, performed for 6 weeks, at least 3 times per day, using video-instructed MP.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurodevelopmental therapy-based exercise therapy (Control group).
Number of subjects: 0
Study: 20814967

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Subcutaneous teriparatide 20 µg
Number of subjects: 412

Group type: COMPARATOR
Intervention: Zoledronic acid 5 mg
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 412
Study: 18281442

Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg) administered before a high-fat or standard breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg) administered concurrently with a standard breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferasirox (20 mg/kg) administered under fasted conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg) administered at least 30 minutes before a meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg) administered consistently at the same time before meals
Number of subjects: 0
Study: 16476694

Group type: EXPERIMENTAL
Intervention: AZD6140 100 mg bid
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: AZD6140 200 mg bid
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: AZD6140 50 mg bid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg qd
Number of subjects: 200
Study: 12965266

Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (IFN-beta1a)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14601905

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by surgery
Number of subjects: 55

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 55
Study: 9663832

Group type: EXPERIMENTAL
Intervention: Electronic data collection system
Number of subjects: 640
Study: 8466418

Group type: EXPERIMENTAL
Intervention: Myoelectric (MYO) prosthetic hand
Number of subjects: 76

Group type: COMPARATOR
Intervention: Body-powered (BP) prosthetic hand
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both MYO and BP prosthetic hands
Number of subjects: 76
Study: 30572339

Group type: EXPERIMENTAL
Intervention: 500-mg Salvia officinalis capsules once a day for 2 consecutive months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo once a day for 2 consecutive months
Number of subjects: 90
Study: 29357859

Group type: EXPERIMENTAL
Intervention: IDN 5933 (Ginkgoselect®Plus) 120 mg twice daily for 6 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 27089068

Group type: EXPERIMENTAL
Intervention: Sequential monotherapy (strategy 1)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Step-up combination therapy (strategy 2)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with prednisone (strategy 3)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with infliximab (strategy 4)
Number of subjects: 508

Group type: COMPARATOR
Intervention: All strategies
Number of subjects: 508
Study: 24891067

Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg per day for 6 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 22340631

Group type: EXPERIMENTAL
Intervention: Cetuximab (250 mg/m2 I.V. on days 1, 8, and 15) + Mitoxantrone (12 mg/m2 I.V. on day 1) + Prednisone (10 mg daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Mitoxantrone (12 mg/m2 I.V. on day 1) + Prednisone (10 mg daily)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Cetuximab (in CMP arm)
Number of subjects: 115
Study: 21127358

Group type: EXPERIMENTAL
Intervention: Closure device (Angio-Seal, St. Jude Medical, Inc.)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Closure device (Angio-Seal, St. Jude Medical, Inc.) in patients with a history of hypertension
Number of subjects: 627

Group type: COMPARATOR
Intervention: Manual compression in patients with a history of hypertension
Number of subjects: 627
Study: 18822128

Group type: EXPERIMENTAL
Intervention: Cues intervention (teaches mothers to attend to their own physiological, cognitive, and emotional cues that signal anxiety and worry, and to use cognitive‐behavioural strategies to reduce distress; also teaches understanding and responding to infant cues)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care group (receives general information about infant care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cues intervention
Number of subjects: 0
Study: 16026370

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion pump (CSII)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 40
Study: 12447952

Group type: EXPERIMENTAL
Intervention: Cefepime or carbapenem monotherapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Combination of cefepime and aminoglycoside
Number of subjects: 165
Study: 10638409

Group type: EXPERIMENTAL
Intervention: 2 mg/kg MDE
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8523940

Group type: EXPERIMENTAL
Intervention: 500 micrograms of inhaled terbutaline for two consecutive days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 500 micrograms of inhaled terbutaline
Number of subjects: 39
Study: 1936483

Group type: EXPERIMENTAL
Intervention: Metformin + SU
Number of subjects: 50

Group type: COMPARATOR
Intervention: Insulin + SU
Number of subjects: 50
Study: 7013087

Group type: EXPERIMENTAL
Intervention: Amitriptyline alone or in combination with fluphenazine hydrochloride
Number of subjects: 10
Study: 31995132

Group type: EXPERIMENTAL
Intervention: Mindful Mood Balance (MMB) plus usual depression care (UDC)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Usual depression care (UDC)
Number of subjects: 460
Study: 31544375

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided acupoint electrical stimulation therapy (30 min, 3 times a day for 7 days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 52
Study: 28628560

Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 2067

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2067
Study: 26402075

Group type: EXPERIMENTAL
Intervention: Nutraceutical formulation (NF: folate, alpha‐tocopherol, B12, S‐adenosyl methionine, N‐acetyl cysteine, acetyl‐L‐carnitine)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 24156189

Group type: EXPERIMENTAL
Intervention: Music Therapy with Emotional‐Approach Coping (MT/EAC)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Talk‐based Emotional‐Approach Coping (EAC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 37
Study: 22368863

Group type: EXPERIMENTAL
Intervention: Ginsenoside Rb1 (10 mg x kg(‐1) administered intraperitoneally once a day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (saline 10 mL x kg(‐1) administered intraperitoneally once a day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Model group (saline 10 mL x kg(‐1) administered intraperitoneally once a day)
Number of subjects: 96
Study: 19702487

Group type: EXPERIMENTAL
Intervention: d‐MPH XR 10 mg o.d.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: d‐MPH XR 20 mg o.d.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: d‐MPH XR 30 mg o.d.
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 17494926

Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine
Number of subjects: 5455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5455
Study: 15510233

Group type: EXPERIMENTAL
Intervention: Budenofalk 9 mg once daily (o.d.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budenofalk 3 mg three times a day (t.i.d.)
Number of subjects: 15
Study: 11562625

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nebulized terbutaline
Number of subjects: 0
Study: 9337466

Group type: EXPERIMENTAL
Intervention: Guided imagery tapes for three days before surgery, during anesthesia induction, intraoperatively, and for six days after surgery
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine perioperative care
Number of subjects: 130
Study: 7886398

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3126348

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) 0.75 mg/kg over 90 min
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intravenous streptokinase 1,500,000 IU over 60 min
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 129

Group type: COMPARATOR
Intervention: streptokinase
Number of subjects: 129
Study: 31680028

Group type: EXPERIMENTAL
Intervention: Wider excision margins (2-3 cm)
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Narrower excision margins (1 cm)
Number of subjects: 1184
Study: 29180023

Group type: EXPERIMENTAL
Intervention: Patiromer (8.4 g/d or 16.8 g/d for 4 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29178713

Group type: EXPERIMENTAL
Intervention: Sonic-active toothbrush (SA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating toothbrush (OR)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All toothbrush systems
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Microbiological analysis
Number of subjects: 72
Study: 26651464

Group type: EXPERIMENTAL
Intervention: AVG group with SDT-based features turned on
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23822942

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) with concurrent phlebectomies
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both EVLA and UGFS
Number of subjects: 100

Group type: COMPARATOR
Intervention: UGFS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adjuvant foam sclerotherapy
Number of subjects: 100
Study: 21982351

Group type: EXPERIMENTAL
Intervention: Formulations with 1.0% and 5.0% panthenol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulations with panthenol after skin washing with sodium laureth sulphate (SLES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control and vehicle (not specified)
Number of subjects: 0
Study: 19393139

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 0
Study: 17050890

Group type: EXPERIMENTAL
Intervention: Endarterectomy
Number of subjects: 527

Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 527
Study: 12873431

Group type: EXPERIMENTAL
Intervention: L-[1-13C] phenylalanine breath test (PBT)
Number of subjects: 25
Study: 10539230

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 334

Group type: COMPARATOR
Intervention: Family-based group intervention
Number of subjects: 334
Study: 8909625

Group type: EXPERIMENTAL
Intervention: Community-based and school-based violence-prevention leadership program for peer leaders and their parents.
Number of subjects: 0
Study: 1855327

Group type: EXPERIMENTAL
Intervention: Vaccination with combined staphylococcus toxoid and whole killed staphylococci (SB)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Normal saline solution (SS)
Number of subjects: 124
Study: 6681030

Group type: EXPERIMENTAL
Intervention: Three-monthly assessments
Number of subjects: 116

Group type: COMPARATOR
Intervention: Yearly assessments
Number of subjects: 116
Study: 30345306

Group type: EXPERIMENTAL
Intervention: Experiencing violence in Italy
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Psychological violence
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Physical violence
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Economic violence
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Intimate partner violence
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Risk factors for violence
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Number of episodes of violence
Number of subjects: 503
Study: 27917802

Group type: EXPERIMENTAL
Intervention: levobupivacaine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: articaine
Number of subjects: 400

Group type: COMPARATOR
Intervention: lidocaine
Number of subjects: 400
Study: 24571702

Group type: EXPERIMENTAL
Intervention: Stabilised stannous (Sn)-containing NaF dentifrice (Oral B/blend-a-Med Pro-Expert)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Clinically proven, stabilised SnF2 positive control (Crest Pro-Health, 1,100 ppm F as SnF2)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Meridol (1,400 ppm F as AmF + SnF2)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Colgate Cavity Protection (1,450 ppm F as SMFP + NaF)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Odol med 3 (1,400 ppm F as NaF)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Elmex (1,400 ppm F as AmF)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Colgate Enamel Protect (1,450 ppm F as NaF + KNO3)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Lacalut aktiv (1,400 ppm F as AlF3)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sensodyne ProNamel (1,450 ppm F as NaF + KNO3)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Crest Cavity Protection (1,100 ppm F as NaF, reference control)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Mentadent (1,450 ppm F as NaF + Zn citrate)
Number of subjects: 4
Study: 22101220

Group type: EXPERIMENTAL
Intervention: Early childhood obesity intervention (no specific dosage or duration mentioned)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Control group (no further intervention mentioned)
Number of subjects: 667
Study: 20331333

Group type: EXPERIMENTAL
Intervention: INJEX needleless device
Number of subjects: 87

Group type: COMPARATOR
Intervention: Classical infiltration anesthesia
Number of subjects: 87
Study: 18246446

Group type: EXPERIMENTAL
Intervention: Experimental group (physicians received instant online graphical output of HRQoL data)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (physicians conducted consultations as usual)
Number of subjects: 162
Study: 16192762

Group type: EXPERIMENTAL
Intervention: Ropivacaine with epinephrine (5 mug/ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ropivacaine without epinephrine
Number of subjects: 20
Study: 14515631

Group type: EXPERIMENTAL
Intervention: Non-submerged loaded (NSL) implants
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Non-submerged non-loaded (NSNL) implants
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Submerged (S) implants
Number of subjects: 14
Study: 10715512

Group type: EXPERIMENTAL
Intervention: School-based tobacco use prevention intervention
Number of subjects: 8388
Study: 8691863

Group type: EXPERIMENTAL
Intervention: 3 units of fresh frozen plasma after operation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gelofusine plasma substitute
Number of subjects: 50
Study: 1549826

Group type: EXPERIMENTAL
Intervention: Weightlifting training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 3890461

Group type: EXPERIMENTAL
Intervention: Topical 1.0% indomethacin (5-drop loading dose, applied pre-operatively and post-operatively every 3 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (25 phakic eyes with capsular glaucoma, lasered without indomethacin drops)
Number of subjects: 24
Study: 31162654

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 0
Study: 29931588

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) combined with functional exercise program (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo group (functional exercise program with placebo phototherapy) (n=11)
Number of subjects: 22
Study: 27302432

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% + epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prilocaine 3% + felypressin 0.03 units
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mepivacaine 3%
Number of subjects: 60
Study: 23338616

Group type: EXPERIMENTAL
Intervention: Intervention only
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Intervention plus follow-up support
Number of subjects: 141

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 141
Study: 23279452

Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar injections containing a local anesthetic (lidocaine 0.5%, 6 mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections of 0.5% lidocaine, 5 mL, mixed with 1 mL of non‐particulate betamethasone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 120
Study: 20167441

Group type: EXPERIMENTAL
Intervention: Standard antiviral HCV therapy with pegylated interferon and ribavirin
Number of subjects: 26
Study: 18322903

Group type: EXPERIMENTAL
Intervention: Beauty treatments during hospitalization
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no beauty treatments)
Number of subjects: 100
Study: 16002160

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: No statin (Control)
Number of subjects: 47
Study: 12796127

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 994
Study: 11042867

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Carbamazepine (BPN/CBZ)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Oxazepam/Carbamazepine (OXA/CBZ)
Number of subjects: 27
Study: 8794707

Group type: EXPERIMENTAL
Intervention: 0.25% fluorometholone
Number of subjects: 140

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups (fluorometholone and vehicle)
Number of subjects: 140
Study: 1378137

Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5-50 mg b.i.d. for 4-8 weeks)
Number of subjects: 65
Study: 3000138

Group type: EXPERIMENTAL
Intervention: 80 mg ACTH 4-9 analogue (Org 2766)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31335838

Group type: EXPERIMENTAL
Intervention: 400 IU/day of vitamin D3
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 800 IU/day of vitamin D3
Number of subjects: 40
Study: 29203083

Group type: EXPERIMENTAL
Intervention: Verbal descriptors + percentage range (n=128)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Percentage range (n=131)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Absolute percentage (n=131)
Number of subjects: 393
Study: 26387883

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) plus usual care (UC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual Care (UC) alone
Number of subjects: 29
Study: 25338425

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: GA
Number of subjects: 71
Study: 23371871

Group type: EXPERIMENTAL
Intervention: Living room theatre activity offered by professional actors (E2)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Living room theatre activity offered by trained caregivers (E1)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Reminiscence group activity (Control)
Number of subjects: 147